This meeting took place in 2002

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Gene-Based Vaccines: Mechanisms, Delivery Systems and Efficacy (D3)

Organizer(s) Margaret A. Liu and Jay A. Berzofsky

April 10—15, 2002

Beaver Run Resort • Breckenridge, CO USA

Abstract Deadline: Dec 10, 2001

Late Abstract Deadline:

Scholarship Deadline:

Early Registration Deadline: Feb 19, 2002

Summary of Meeting:Gene-based vaccines (both plasmid- and vector-based) are considered a most promising approach for making both prophylactic and therapeutic vaccines against a number of infectious diseases and cancer. These vaccines can induce the cytolytic T cell responses thought to be critical for many viral and parasitic diseases and cancer more effectively than protein-based or killed-organism vaccines, yet do not have the potential risk that attenuated viruses may have. In addition, they may have a number of other technological advantages for vaccines needed on a global scale. However, to date, a number of fundamental issues need to be solved, including increasing the potency of the vaccines by understanding the mechanisms of DNA uptake and antigen presentation, and determining how to harness the unexpected immunostimulatory effects of DNA itself. This meeting will provide the opportunity to bring together scientists from a variety of disciplines (microbiology, virology, cell biology, vaccinology, gene therapy, oncology, infectious diseases, polymer chemistry) to address the fundamental cellular mechanisms involved, within the context of the greater immunological issues.

Arya Biragyn,
NIA, National Institutes of Health, USA
Pro-Inflammatory Chemokine or beta-Defensin Mediated Targeting of Immature DC Elicit Potent Antitumor Protective and Therapeutic Immunity. Implication for the Development of AIDS and Other Vaccines

James P. Allison,
University of Texas MD Anderson Cancer Center, USA
More is Less: New Insights into the Mechanisms of Negative Costimulation by CTLA-4 and its Manipulation in the Enhancement of T Cell Responses

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

If your organization is interested in joining these entities in support of Keystone
Symposia, please contact:&nbspSarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org,Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.